Novo Nordisk Initiates Share Repurchase Program
Ticker: NONOF · Form: 6-K · Filed: Nov 18, 2024 · CIK: 353278
Sentiment: neutral
Topics: share-repurchase, regulation, disclosure
TL;DR
Novo Nordisk is buying back its own stock under EU regulations.
AI Summary
Novo Nordisk A/S announced on November 18, 2024, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance with European regulations, specifically Article 5 of Regulation No 596/2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052.
Why It Matters
Share repurchases can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of a share repurchase program, which is a common corporate action.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- Regulation No 596/2014 (regulation) — Governing share repurchase program
- Commission Delegated Regulation (EU) 2016/1052 (regulation) — Governing share repurchase program
FAQ
When did Novo Nordisk initiate its share repurchase program?
Novo Nordisk initiated its share repurchase program on November 11, 2024.
What regulations govern this share repurchase program?
The program is governed by Article 5 of Regulation No 596/2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052.
What is the filing date of this report?
This Form 6-K report was filed on November 18, 2024.
What is the company's principal executive office address?
The principal executive offices are located at Novo Allé 1 DK- 2880, Bagsvaerd Denmark.
Is Novo Nordisk filing an annual report under Form 20-F or 40-F?
Novo Nordisk indicated it files annual reports under cover of Form 20-F.
Filing Stats: 659 words · 3 min read · ~2 pages · Grade level 10.1 · Accepted 2024-11-18 11:19:11
Filing Documents
- f6k_111824.htm (6-K) — 21KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-24-006420.txt ( ) — 160KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: November 18, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer